Chugai Pharmaceutical Co., Ltd. Chugai Pharmaceutical Co., Ltd.

Chugai Pharmaceutical Co., Ltd.

4519

Clasificación en acciones #353
Chugai Pharmaceutical Co., Ltd. is a prominent global pharmaceutical company,... Chugai Pharmaceutical Co., Ltd. is a prominent global pharmaceutical company, operating subsidiaries involved in the full lifecycle of drug development, from research and manufacturing to sales, import, and export, serving both Japanese and international markets. Its commercialized product portfolio spans several key therapeutic areas. These include a robust oncology offering with leading treatments like Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda. Additionally, it provides medications for bone health (e.g., Actemra, Edirol, Bonviva), renal conditions (such as Mircera and Oxarol), and neurological or other diverse ailments (including Hemlibra, CellCept, and Enspryng). Beyond its existing offerings, the company maintains an active research and development pipeline. This pipeline features multiple promising candidates targeting oncology, orthopedic and joint disorders, autoimmune diseases, kidney-related conditions, and various neurological or other health issues. Strategic partnerships are central to Chugai's operations, most notably a significant alliance with the Roche Group. The company also fosters collaborative research initiatives with academic institutions. Established in 1925, Chugai's headquarters are located in Tokyo, Japan, and it operates as a key subsidiary of Roche Holding Ltd.
Precio por acción
$41.34
Capitalización bursátil
$68.04B
Cambio (1 día)
0.05%
Cambio (1 año)
-12.50%
País
JP
Comercio Chugai Pharmaceutical Co., Ltd. (4519)

Categoría

Healthcare
Ratio P/S de Chugai Pharmaceutical Co., Ltd. (4519)
Ratio P/S al 2026 TTM: 0
Según los informes financieros más recientes y el precio de las acciones de Chugai Pharmaceutical Co., Ltd., el ratio P/S actual (TTM) es 0. Al final de 2026, el ratio P/S era 0.
Historial del ratio P/S de Chugai Pharmaceutical Co., Ltd. desde 2026 hasta 2026
Ratio P/S al final de cada año
Año Ratio P/S Cambiar
Not enough data for the provided dates.
Ratio P/S de empresas similares o competidoras
Empresa Ratio P/S Diferencia del ratio P/S País
14.32 -
US
6.16 -
US
7.78 -
US
5.48 -
US
4.66 -
CH